Dowling & Yahnke LLC Has $5.07 Million Position in Eli Lilly and Company (LLY)

Dowling & Yahnke LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 61,575 shares of the company’s stock after purchasing an additional 544 shares during the quarter. Dowling & Yahnke LLC’s holdings in Eli Lilly and were worth $5,068,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Heritage Trust Co acquired a new position in Eli Lilly and during the 1st quarter valued at approximately $135,000. Point72 Asia Hong Kong Ltd boosted its position in Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares during the period. Shine Investment Advisory Services Inc. acquired a new position in Eli Lilly and during the 2nd quarter valued at approximately $148,000. Cornerstone Advisors Inc. boosted its position in Eli Lilly and by 18.4% during the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock valued at $166,000 after purchasing an additional 313 shares during the period. Finally, Penserra Capital Management LLC boosted its position in Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after purchasing an additional 176 shares during the period. Institutional investors and hedge funds own 75.72% of the company’s stock.

WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/10/11/dowling-yahnke-llc-has-5-07-million-position-in-eli-lilly-and-company-lly.html.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the sale, the insider now directly owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 990,000 shares of company stock worth $82,949,650. 0.20% of the stock is owned by corporate insiders.

Shares of Eli Lilly and Company (NYSE LLY) opened at 86.16 on Wednesday. The company has a market cap of $90.90 billion, a P/E ratio of 37.28 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The stock has a 50 day moving average price of $82.75 and a 200-day moving average price of $82.15.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.86 EPS. Analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

LLY has been the subject of a number of analyst reports. Piper Jaffray Companies restated a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a research note on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $89.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Cowen and Company reaffirmed a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research note on Thursday, July 27th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $88.57.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply